Saturday 17 October 2026
Export KURA’s income statement to Excel — free account
Kura Oncology, Inc.
KURA Healthcare Biotechnology
Kura Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.5 million, up 25.2% from fiscal 2024. In the quarter to June 2026, revenue grew 36.5%, EPS fell 2.67%, free cash flow fell 109.1% and total debt rose 1.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.08
0.62
−6.39%
Follow KURA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.62 | 10.06 | 13.50 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 9.33 | |
P/Operating CF |
(15.58) | (8.39) | 7.77 | (9.62) | |
P/B ratio |
20.13 | 6.68 | 5.23 | 3.20 | |
Price to Tangible BV |
20.13 | 6.68 | 5.23 | 3.20 | |
EV/Sales |
6.03 | 2.15 | 3.82 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.17) | (1.97) | (4.02) | 2.68 | |
EV/FCF |
(3.96) | (1.82) | (3.65) | 2.84 | |
Quick Ratio |
4.47 | 5.81 | 5.78 | 4.83 | |
Current Ratio |
4.73 | 6.15 | 6.06 | 5.12 | |
Net Debt/EBITDA |
6.94 | 7.20 | 7.54 | 6.60 | |
Debt/Assets |
1.67% | 1.49% | 1.32% | 1.49% | |
Debt/Equity |
0.20 | 0.09 | 0.06 | 0.04 | |
Asset Turnover |
0.12 | 0.10 | 0.09 | 0.00 | |
Operating CF/Net income |
0.92 | 1.17 | (1.45) | 1.09 | |
Capex/Depreciation |
1.76 | 0.23 | 2.37 | 1.46 | |
Interest Coverage |
(211.62) | (234.57) | (249.33) | (203.55) | |
Research and Development Expense of Revenue |
296.50% | 357.31% | 371.53% | 327.27% | |
Selling, General and Administrative Expense of Revenue |
152.10% | 172.76% | 225.77% | 158.26% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
39.33% | 46.08% | 65.48% | 52.84% | |
Graham Net Nets |
0.02 | 0.11 | 0.16 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(30.72%) | (41.21%) | (30.61%) | (28.02%) | |
Free Cash Flow Yield |
(12.05%) | (11.72%) | (7.76%) | 10.71% | |
Revenue per Share |
0.23 | 0.21 | 0.20 | 0.24 | |
Operating CF per Share |
(0.70) | (0.97) | 1.34 | (0.92) | |
Capex per Share |
(0.01) | 0.00 | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.71) | (0.97) | 1.31 | (0.95) | |
Cash per Share |
5.84 | 6.55 | 7.61 | 6.27 | |
Shareholders Equity per Share |
0.55 | 1.22 | 1.99 | 2.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.55 | 1.22 | 1.99 | 2.77 | |
Free Cash Flow |
(63.20) | (85.98) | 114.95 | (83.19) | |
Working Capital |
441.25 | 522.29 | 591.69 | 499.36 | |
Capital Expenditures |
(0.66) | (0.13) | (2.32) | (2.57) | |
Net Current Asset Value |
20.08 | 79.11 | 144.44 | 213.82 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.13 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.01 | 29.05 | 5.43 | 17.98 | |
Average Payables |
27.66 | 26.07 | 3.24 | 51.88 | |
Average Assets |
635.11 | 698.16 | 749.26 | 564.11 | |
Average Common Equity |
176.96 | 236.14 | 293.89 | 333.16 |
Columns are period end dates